Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

Ro 48-8071 fumarate

A selective 2,3-Oxidosqualene:lanosterol cyclase (OSC) inhibitor
Catalog #: B1042
SKU-Size Size Price Qty
B1042-10 10 mg
$115.00
B1042-50 50 mg
$455.00
More Sizes Get Quote

Product Details

Alternate Name (4-Bromophenyl)[2-fluoro-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]phenyl]methanone fumarate
Appearance Off-white solid
CAS # 189197-69-1
Molecular Formula C₂₃H₂₇BrFNO₂.C₄H₄O₄
Molecular Weight 564.44
Purity ≥98% by HPLC
Solubility DMSO (>50 mg/ml) or H₂O (>5 mg/ml)
SMILES CN(CCCCCCOC1=CC(=C(C=C1)C(=O)C2=CC=C(C=C2)Br)F)CC=C.C(=CC(=O)O)C(=O)O
InChi InChI=1S/C23H27BrFNO2.C4H4O4/c1-3-14-26(2)15-6-4-5-7-16-28-20-12-13-21(22(25)17-20)23(27)18-8-10-19(24)11-9-18;5-3(6)1-2-4(7)8/h3,8-13,17H,1,4-7,14-16H2,2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
InChi Key XCYAYLWZCRGKDS-WLHGVMLRSA-N
PubChem CID 9959583
Handling Protect from air and moisture
Storage Conditions -20°C
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.

Details

Ro 48-8071 is a selective 2,3-Oxidosqualene:lanosterol cyclase (OSC) inhibitor (IC₅₀ = 6.5 nM); blocks cholesterol synthesis in HepG2 cells. Ro 48-8071 exerts strong anti-angiogenic activity by impairing endothelial cell adhesion and migration, and by blocking vessel formation in angiogenesis assays.


Why buy BioVision Products?
Innovation
Affordability
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.